# Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

> **NCT03384836** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Roswell Park Cancer Institute** · enrollment: 47 (estimated)

## Conditions studied

- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Propranolol Hydrochloride

## Key facts

- **NCT ID:** NCT03384836
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2018-01-31
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 47 (ESTIMATED)
- **Why stopped:** interim Analysis
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03384836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03384836, "Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT03384836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*